Last reviewed · How we verify
NCT05485714
Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
trial testing Reviewing records retrospectively of patients undergoing screening endoscopy in Esophageal Varices in 73 participants. Completed in 1 August 2023.
1 May 2023
Quick facts
| Lead sponsor | United Arab Emirates University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 73 |
| Start date | 5 October 2022 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across United Arab Emirates |
Drugs / interventions tested
- Reviewing records retrospectively of patients undergoing screening endoscopy
Conditions studied
- Esophageal Varices — all drugs for Esophageal Varices →
- Non-alcoholic Fatty Liver — all drugs for Non-alcoholic Fatty Liver →
- Compensated Cirrhosis — all drugs for Compensated Cirrhosis →
Sponsor
United Arab Emirates University
Who can join
Adults 18 to 80, any sex, with Esophageal Varices or Non-alcoholic Fatty Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection, immune-mediated, or medication related which can lead to fibrosis and later-on, cirrhosis. Over the last years NAFLD related liver cirrhosis has become the commonest cause of chronic liver disease worldwide. Portal hypertension is the major complication caused by increased splanchnic blood flow which leads to development of oesophageal varices (OV). Almost all of the patients with portal hypertension can develop OV sometime in their life and one third of those will bleed, hence identifying the presence of OV is a an important aspect of diagnostic workup of these patients with portal hypertension. Upper digestive camera test/endoscopy is the only means to diagnose and grade OV but endoscopy is an invasive procedure and its cost effectiveness for screening is also questionable. These limitations and the ever-increasing workload on endoscopy units has led many researchers to identify some parameters that can non-invasively diagnose OV. Researchers have proposed use of platelet count/spleen diameter ratio, liver stiffness on Fibroscan among many non-invasive tools to predict OV in patients with portal hypertension with success. Recently criteria proposed in Baveno VI conference, (Baveno-IV Criteria) recommended that screening endoscopy can be avoided in patients with compensated advanced chronic liver disease (cACLD) with liver stiffness measurement (LSM) less than 20 kPa and a platelet count more than than 150,000/μL with an expanded Baveno-IV criteria suggesting platelet count \>110 × 109 cells/L and LSM \<25 kPa can spare even more endoscopies with a risk of missing varices needing treatment (VNT) being minimal.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring new noninvasive parameters to predict oesophageal varices in patients with NAFLD-associated compensated liver cirrhosis.
Agha A, Pasta A, Calabrese F, Anwar E, et al · · 2025 · PMID 40191516 · DOI 10.5114/pg.2024.139210
Verify or expand the search:
- PubMed search for NCT05485714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Varices
Currently open trials in the same condition.
- NCT07122622 — 2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices · recruiting
- NCT06881082 — Cross-section Band Ligation Versus Stepladder Band Ligation of Esophageal Varices · NA · recruiting
- NCT05979935 — A Digital Tongue Diagnosis Model for High- and Low-risk Esophagogastroduodenal Varices in Cirrhosis · active not recruiting
- NCT04499898 — Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding · Phase 2, PHASE3 · recruiting
Other United Arab Emirates University trials
Trials by the same sponsor.
- NCT07042412 — Ta'am Mustadam Intervention to Promote Sustainable Food Choices · NA · active not recruiting
- NCT07491705 — Camel Milk Impact on Aerobic Exercise Recovery, Induced Inflammation, and Physical Performance · NA · completed
- NCT06595225 — Nutrition Education Intervention for PLHIV · NA · completed
- NCT05481021 — Burnout Syndrome Among Diabetes Specialist Trainee Registrars in United Kingdom · completed
- NCT04688684 — The Emirates Heart Health Project: A Family-based Diet and Exercise Intervention in Obese and Overweight Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05485714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by United Arab Emirates University
- Last refreshed: 11 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05485714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing